104 related articles for article (PubMed ID: 23645733)
1. Broussoflavonol B restricts growth of ER-negative breast cancer stem-like cells.
Guo M; Wang M; Zhang X; Deng H; Wang ZY
Anticancer Res; 2013 May; 33(5):1873-9. PubMed ID: 23645733
[TBL] [Abstract][Full Text] [Related]
2. A novel anticancer agent Broussoflavonol B downregulates estrogen receptor (ER)-α36 expression and inhibits growth of ER-negative breast cancer MDA-MB-231 cells.
Guo M; Wang M; Deng H; Zhang X; Wang ZY
Eur J Pharmacol; 2013 Aug; 714(1-3):56-64. PubMed ID: 23769740
[TBL] [Abstract][Full Text] [Related]
3. Broussoflavonol B from
Jeong JH; Ryu JH
Molecules; 2020 May; 25(10):. PubMed ID: 32429421
[TBL] [Abstract][Full Text] [Related]
4. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023
[TBL] [Abstract][Full Text] [Related]
5. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
Zhang X; Deng H; Wang ZY
J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
[TBL] [Abstract][Full Text] [Related]
6. ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells.
Deng H; Zhang XT; Wang ML; Zheng HY; Liu LJ; Wang ZY
PLoS One; 2014; 9(2):e88034. PubMed ID: 24558373
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells.
Pan X; Zhao B; Song Z; Han S; Wang M
J Pharmacol Sci; 2016 Feb; 130(2):85-93. PubMed ID: 26810571
[TBL] [Abstract][Full Text] [Related]
8. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.
Wang ZY; Yin L
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer stem cell activity of a hedgehog inhibitor GANT61 in estrogen receptor-positive breast cancer cells.
Kurebayashi J; Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T
Cancer Sci; 2017 May; 108(5):918-930. PubMed ID: 28211214
[TBL] [Abstract][Full Text] [Related]
12. Characteristic Binding Landscape of Estrogen Receptor-α36 Protein Enhances Promising Cancer Drug Design.
Adewumi AT; Mosebi S
Biomolecules; 2023 Dec; 13(12):. PubMed ID: 38136668
[TBL] [Abstract][Full Text] [Related]
13. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
[TBL] [Abstract][Full Text] [Related]
15. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
[TBL] [Abstract][Full Text] [Related]
16. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
[TBL] [Abstract][Full Text] [Related]
17. A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells.
Kang L; Guo Y; Zhang X; Meng J; Wang ZY
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):262-8. PubMed ID: 21907803
[TBL] [Abstract][Full Text] [Related]
18. A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.
Zhan Y; Zhang Y; Liu C; Zhang J; Smith WW; Wang N; Chen Y; Zheng L; He L
Cancer Prev Res (Phila); 2012 Jun; 5(6):864-73. PubMed ID: 22496388
[TBL] [Abstract][Full Text] [Related]
19. ER-α36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen Resistance.
Teymourzadeh A; Mansouri S; Farahmand L; Hosseinzade A; Majidzadeh-A K
Clin Breast Cancer; 2017 Oct; 17(6):403-407. PubMed ID: 28433540
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
Yang Z; Barnes CJ; Kumar R
Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
